Is too much of a good thing a bad thing? Seems perhaps so when it comes to exercising. Studies in various journals have looked at the impact of gyms, personal trainers, and health clubs on the world and are questioning whether this “exercise addiction” is a socially acceptable practice despite its parallel to eating disorders. Looking good is great, but what is the overall cost to your health?

Simone Gold, MD, JD, a California doctor, and founder of America’s Frontline Doctors who has touted the benefits of hydroxychloroquine and raised unfounded concerns about the COVID-19 vaccines, admitted to the Washington Post that she joined the mob that stormed the Capitol last Wednesday. She added that she followed a crowd inside the building and assumed it was legal to do so.

Some researchers have found that as many as 50% of clinicians suffer from burnout, defined as a long-term stress reaction causing emotional exhaustion, depersonalization, and other symptoms that affect quality of life and physical health. According to a study published in the Journal of the American Heart Association, this specific condition is being seen in those in high-pressure fields more regularly than others.

Rehabilitation psychologist Abigail Hardin, PhD, of Rush University Medical Center offers some advice to those waiting for the COVID-19 vaccine, which is especially important given that the vaccines don’t take full effect (around 95% immunity) until days or weeks a number of days after the second dose. She recommends taking a few key steps now to reduce some of the challenges and anxieties that come with a serious illness.

The term abscopal effect (from Latin, ab, meaning “away from,” and scopus, meaning “target”) was coined in 1953, specifically referring to effects of ionizing radiation outside the radiated tumor volume. Does the evidence show that, contrary to widely held perception in the field, the abscopal effect is exceedingly rare and is not clinically relevant when using anti–PD-1/PD-L1 therapies and stereotactic body radiation therapy (SBRT) for head and neck cancer (HNC)?

From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when treating patients with CLL.